Taro Provides Results for Quarter Ended June 30, 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Taro Pharma (TARO) Reports Q1 Loss of $11.37 on Revenues of $117.6M
July 29, 2020 5:11 PM EDTTaro Pharma (NYSE: TARO) reported Q1 EPS of ($11.37), versus $1.72 reported last year. Revenue for the quarter came in at $117.6 million versus the consensus estimate of $158.35 million.
Quarter ended June 30, 2020 Highlights - compared to Quarter ended June 30, 2019
Net sales of $117.6 million, decreased $43.7 million.Gross profit of $64.9 million decreased $36.8 million, and as a percentage of net sales was 55.2% compared to 63.1%.Research and development expenses of $12.9 million decreased slightly from the prior year.Selling, marketing, general and administrative expenses of $22.2 million, which includes the impact of COVID-19 related... More